Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | PLG | P00747 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4746775 | 0.92 | THRB (0.44) | PAOXTHRBKMT2AALDH1A1LMNA | |
| SCHEMBL11476302 | 0.84 | FNTA (0.62) | THRBKMT2AALDH1A1MEN1ALOX15 | |
| SCHEMBL523846 | 0.84 | THRB (0.36) | PAOXTHRBKMT2AALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL9636093 | 0.82 | THRB (0.35) | PAOXTHRBKMT2AALDH1A1LMNA | |
| Bromide SCHEMBL7686683 | 0.82 | THRB (0.35) | PAOXTHRBKMT2AALDH1A1LMNA | |
| SCHEMBL3259746 | 0.82 | FNTA (0.59) | THRBKMT2AALDH1A1MEN1ALOX15 | |
| SCHEMBL3259749 | 0.82 | FNTA (0.59) | THRBKMT2AALDH1A1MEN1ALOX15 | |
| SCHEMBL1934407 | 0.80 | PAOX (0.45) | PAOXTHRBKMT2AALDH1A1LMNA | |
| Chloromethane SCHEMBL6137819 | 0.80 | THRB (0.34) | PAOXTHRBKMT2AALDH1A1LMNA | |
| SCHEMBL8930241 | 0.76 | FNTA (0.45) | THRBKMT2AALDH1A1MEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8409561-B2 | Methods and compositions for treatment of ion imbalances | RELYPSA, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-1732524-B1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | RELYPSA INC (US) | 2012-08-22 | — | — | EP | disclosed |
| US-8147873-B2 | Administering sodium binding polymer; hypotensive agents; cardiovascular disorders, liver disorders; crosslinking fluoroacrylic acid | RELYPSA, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110033505-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | RELYPSA, INC. (US) | 2011-02-10 | — | — | US | disclosed |
| US-7854924-B2 | Methods and compositions for treatment of ion imbalances | RELYPSA, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7776319-B2 | Administering sodium-binding polymer of a core-shell, having an in vivo sodium binding capacity of 4 mmol or more per gram of polymer for removing sodium in gastro-intestinal tract ; treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, fluid overload | RELYPSA, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080260679-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | RELYPSA, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| EP-1732524-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | ILYPSA INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1732524-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | Ilypsa, Inc. (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060024265-A1 | Administering sodium-binding polymer of a core-shell, having an in vivo sodium binding capacity of 4 mmol or more per gram of polymer for removing sodium in gastro-intestinal tract ; treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, fluid overload | VIFOR (INTERNATIONAL) LTD. (CH) | 2006-02-02 | — | — | US | disclosed |
| WO-2005094384-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | ILYPSA, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| US-20050220750-A1 | Methods and compositions for treatment of ion imbalances | SYMYX THERAPEUTICS, INC. (US) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260679-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | SLC10A1, SLC9A5, SLC9A3 | PAOX 1577/4885THRB 1932/4885KMT2A 4639/4885 |
| US-20060024265-A1 | Administering sodium-binding polymer of a core-shell, having an in vivo sodium binding capacity of 4 mmol or more per gram of polymer for removing sodium in gastro-intestinal tract ; treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, fluid overload | SLC10A2, SLC10A1, SLC9A3 | PAOX 3346/4885THRB 2694/4885KMT2A 4506/4885 |
| US-20110033505-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF ION IMBALANCES | SLC10A1, SLC9A5, SLC9A3 | PAOX 1577/4885THRB 1932/4885KMT2A 4639/4885 |
| US-20050220750-A1 | Methods and compositions for treatment of ion imbalances | SLC10A1, SLC9A5, SLC9A3 | PAOX 1577/4885THRB 1932/4885KMT2A 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.